Vecabrutinib - Sunesis Pharmaceuticals

Drug Profile

Vecabrutinib - Sunesis Pharmaceuticals

Alternative Names: SNS 062

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Biogen; Sunesis Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies

Most Recent Events

  • 14 Jun 2018 Pharmacodynamics data from a preclinical trial in Lymphoma presented at 23rd Congress of the European Haematology Association (EHA- 2018)
  • 01 May 2017 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Chronic lymphocytic leukaemia presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 28 Apr 2017 Phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (PO) (NCT03037645)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top